Please join Galectin Therapeutics for a virtual key opinion leader (KOL) event focused on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

• Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program at Indiana University School of Medicine; and
• Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer at Summit Clinical Research San Antonio, TX and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH

The event will highlight updated results from Galectin’s NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal hypertension. These results reinforce and extend previously reported findings supporting the antifibrotic and disease-modifying potential of belapectin. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin may represent the first potential treatment to address this significant unmet need.

A live question and answer session will follow the formal presentations.